Castle Biosciences Net Income
| CSTL Stock | USD 32.23 0.52 1.59% |
As of the 9th of February, Castle Biosciences shows the Risk Adjusted Performance of (0.02), standard deviation of 2.6, and Mean Deviation of 1.67. Castle Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Castle Biosciences market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Castle Biosciences is priced correctly, providing market reflects its regular price of 32.23 per share. Given that Castle Biosciences has information ratio of (0.08), we suggest you to validate Castle Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.
Castle Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Castle Biosciences' valuation are provided below:Castle Biosciences does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. Projected growth potential of Castle fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Castle Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Castle Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Castle Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Castle Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Castle Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Castle Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Castle Biosciences.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Castle Biosciences on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Castle Biosciences or generate 0.0% return on investment in Castle Biosciences over 90 days. Castle Biosciences is related to or competes with Myriad Genetics, CareDx, Personalis, Fulgent Genetics, Evolent Health, Geron, and DarioHealth Corp. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing s... More
Castle Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Castle Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Castle Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.27 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 3.28 |
Castle Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Castle Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Castle Biosciences' standard deviation. In reality, there are many statistical measures that can use Castle Biosciences historical prices to predict the future Castle Biosciences' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (1.43) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Castle Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Castle Biosciences February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (1.42) | |||
| Mean Deviation | 1.67 | |||
| Coefficient Of Variation | (2,667) | |||
| Standard Deviation | 2.6 | |||
| Variance | 6.76 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (1.43) | |||
| Maximum Drawdown | 16.27 | |||
| Value At Risk | (2.88) | |||
| Potential Upside | 3.28 | |||
| Skewness | (1.29) | |||
| Kurtosis | 4.65 |
Castle Biosciences Backtested Returns
Castle Biosciences secures Sharpe Ratio (or Efficiency) of -0.0375, which signifies that the company had a -0.0375 % return per unit of risk over the last 3 months. Castle Biosciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Castle Biosciences' Mean Deviation of 1.67, risk adjusted performance of (0.02), and Standard Deviation of 2.6 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.0753, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Castle Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Castle Biosciences is expected to be smaller as well. At this point, Castle Biosciences has a negative expected return of -0.0974%. Please make sure to confirm Castle Biosciences' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Castle Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.22 |
Weak reverse predictability
Castle Biosciences has weak reverse predictability. Overlapping area represents the amount of predictability between Castle Biosciences time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Castle Biosciences price movement. The serial correlation of -0.22 indicates that over 22.0% of current Castle Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.22 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 7.21 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Castle Biosciences reported net income of 18.25 M. This is 94.65% lower than that of the Biotechnology sector and 89.46% lower than that of the Health Care industry. The net income for all United States stocks is 96.8% higher than that of the company.
Castle Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Castle Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics of similar companies.Castle Biosciences is currently under evaluation in net income category among its peers.
Castle Fundamentals
| Return On Equity | -0.027 | ||||
| Return On Asset | -0.0172 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 705.82 M | ||||
| Shares Outstanding | 29.19 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 90.61 % | ||||
| Number Of Shares Shorted | 1.53 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 2.05 X | ||||
| Price To Sales | 2.78 X | ||||
| Revenue | 332.07 M | ||||
| Gross Profit | 274.63 M | ||||
| EBITDA | 38.14 M | ||||
| Net Income | 18.25 M | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 26.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 16.02 X | ||||
| Cash Flow From Operations | 64.87 M | ||||
| Short Ratio | 4.54 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 48.57 | ||||
| Number Of Employees | 823 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 955.93 M | ||||
| Total Asset | 531.24 M | ||||
| Retained Earnings | (200.13 M) | ||||
| Working Capital | 310.76 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
| Net Asset | 531.24 M |
About Castle Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Castle Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. Projected growth potential of Castle fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Castle Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Castle Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Castle Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Castle Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.